New Immunotherapeutic Approaches for Glioblastoma
Por:
Vázquez Cervantes G.I., González Esquivel D.F., Gómez-Manzo S., Pineda B., Pérez de la Cruz V.
Publicada:
1 ene 2021
Resumen:
Glioblastoma (GBM) is the most common primary malignant brain tumor with a high mortality rate. The current treatment consists of surgical resection, radiation, and chemotherapy; however, the median survival rate is only 12-18 months despite these alternatives, highlighting the urgent need to find new strategies. The heterogeneity of GBM makes this tumor difficult to treat, and the immunotherapies result in an attractive approach to modulate the antitumoral immune responses favoring the tumor eradication. The immunotherapies for GMB including monoclonal antibodies, checkpoint inhibitors, vaccines, and oncolytic viruses, among others, have shown favorable results alone or as a multimodal treatment. In this review, we summarize and discuss promising immunotherapies for GBM currently under preclinical investigation as well as in clinical trials. © 2021 Gustavo Ignacio Vázquez Cervantes et al.
Filiaciones:
Vázquez Cervantes G.I.:
Neurochemistry and Behavior Laboratory, National Institute of Neurology and Neurosurgery Manuel Velasco Suárez, Mexico City, 14269, Mexico
Posgrado en Ciencias Biológicas, Unidad de Posgrado, Edificio A, Ciudad Universitaria, 1° Piso, Circuito de Posgrados, Distrito Federal, Coyoacán, C.P. 04510, Mexico
González Esquivel D.F.:
Neurochemistry and Behavior Laboratory, National Institute of Neurology and Neurosurgery Manuel Velasco Suárez, Mexico City, 14269, Mexico
Gómez-Manzo S.:
Laboratorio de Bioquímica Genética, Instituto Nacional de Pediatría, Secretaría de Salud, Mexico City, 04530, Mexico
Pineda B.:
Neuroimmunology Department, National Institute of Neurology and Neurosurgery Manuel Velasco Suárez, Mexico City, 14269, Mexico
Pérez de la Cruz V.:
Neurochemistry and Behavior Laboratory, National Institute of Neurology and Neurosurgery Manuel Velasco Suárez, Mexico City, 14269, Mexico
Gold
|